CORONA Remedies Q3 FY26: Revenue up 15%, PAT up 23.7% YoY
CORONA Remedies reported a strong Q3 FY26 with consolidated revenue up 15.0% YoY to ₹342.42 Cr and PAT up 23.7% YoY to ₹55.56 Cr. For nine months FY26, revenue grew 16.3% to ₹1050.09 Cr and PAT increased 30.7% to ₹154.08 Cr. The company achieved its guided targets for revenue and PAT growth. An earnings call is scheduled for February 03, 2026.
The announcement details strong financial results with substantial year-on-year growth in key metrics like revenue and PAT, along with confirmation of achieving guided targets. This is a material development for investors and the company's market position.
The company reported significant year-on-year growth in both revenue and profit after tax, exceeding its own guided targets, which indicates a positive financial performance.
CORONA Remedies Limited announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these results during a meeting held on February 02, 2026, which commenced at 04:00 p.m. and concluded at 05:15 p.m.
For the third quarter of FY26, the consolidated revenue from operations stood at ₹342.42 crore, marking a 15.0% year-on-year growth. Profit After Tax (PAT) for the quarter was ₹55.56 crore, an increase of 23.7% compared to the same period last year. The company also reported EBITDA of ₹83.16 crore and an EBITDA margin of 24.3% for Q3 FY26. The PAT margin for the quarter was 16.2%.
For the nine months ended December 31, 2025, consolidated revenue from operations reached ₹1050.09 crore, a year-on-year growth of 16.3%. PAT for the nine-month period was ₹154.08 crore, reflecting a significant increase of 30.7% year-on-year. The company reported an EBITDA of ₹231.42 crore for the nine months, with an EBITDA margin of 22.0% and a PAT margin of 14.7%.
Key financial metrics for the nine months FY26 include a Return on Equity (RoE) of 31.1%, Return on Capital Employed (RoCE) of 48.0%, and an OCF to EBITDA ratio of 86.3%. Net Working Capital Days were reported at 18 days. These figures exclude a one-time statutory impact of the New Labour Code amounting to ₹19.10 crore (post-tax ₹14.29 crore).
Mr. Nirav K. Mehta, Managing Director and CEO of CORONA Remedies Limited, expressed delight with the strong financial performance, highlighting that the company has consistently delivered on its guided aspirations of growing Revenues by 15% and PAT by 20%. He attributed the performance to a consistent strategy, disciplined execution, and a focus on core therapeutic segments, including strengthening the field force and expanding the brand portfolio.
The company will publish an advertisement for the unaudited financial results in accordance with Listing Regulations. The results and limited review reports are also available on the company's website, www.coronaremedies.com.
CORONA Remedies Limited will conduct an earnings call on Tuesday, February 03, 2026, at 4:00 PM IST to discuss the financial and business performance.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.